Active Ingredient(s):Binimetinib FDA Approved: * June 27, 2018 Pharm Company: *ARRAY BIOPHARMA INC Category:Cancer
Binimetinib, also known as Mektovi and ARRY-162, is an anti-cancer small molecule that was developed by Array Biopharma to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers. In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresec...
* May have multiple approval dates, manufacturers, or labelers.